Cost-effectiveness of rosuvastatin for cardiovascular prevention in high-risk populations in Sweden

被引：0
|
作者：
Jonsson, L.
Ekman, M.
Karlsson, G.
Brun, J.
机构：
[1] European Hlth Econ, London, England
[2] Stockholm Hlth Econ, Stockholm, Sweden
[3] AstraZeneca, Sodertalje, Sweden
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)63646-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A346 / A346
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of cardiovascular prevention programs in Spain
    Plans-Rubio, P
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1998, 14 (02) : 320 - 330
  • [22] COST-EFFECTIVENESS OF ROSUVASTATIN/EZETIMIBE THERAPY IN HIGH-RISK HYPERTENSIVE PATIENTS WITH UNCONTROLLED HYPERCHOLESTEROLEMIA BY A PREVIOUS SIMVASTATIN/EZETIMIBE TREATMENT
    Mazza, A.
    Torin, G.
    D'Amicis, C.
    Schiavon, L.
    Sacco, A. P.
    Lenti, S.
    JOURNAL OF HYPERTENSION, 2019, 37 : E228 - E228
  • [23] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN
    Villa, G.
    Lothgren, M.
    Kutikova, L.
    Lindgren, P.
    Gandra, S. R.
    Fonarow, G. C.
    Sorio, F.
    Masana, L.
    Bayes-Genis, A.
    van Hout, B.
    VALUE IN HEALTH, 2016, 19 (07) : A651 - A652
  • [24] Cost-effectiveness of influenza vaccination in high-risk children in Argentina
    Dayan, GH
    Nguyen, VH
    Debbag, R
    Gómez, R
    Wood, SC
    VACCINE, 2001, 19 (30) : 4204 - 4213
  • [25] Cost-effectiveness of bisphosphonate therapy in high-risk osteoporotic women
    Grima, D
    Burge, RT
    Becker, D
    Tosteson, ANA
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S82 - S83
  • [26] Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
    Villa, Guillermo
    Lothgren, Mickael
    Kutikova, Lucie
    Lindgren, Peter
    Gandra, Shravanthi R.
    Fonarow, Gregg C.
    Sorio, Francesc
    Masana, Lluis
    Bayes-Genis, Antoni
    van Hout, Ben
    CLINICAL THERAPEUTICS, 2017, 39 (04) : 771 - 786
  • [27] Cost-effectiveness of antifungal strategies in high-risk neutropenic patients
    Schwarzinger, Michael
    Baillot, Sylvain
    Beauchamp, Celine
    Maury, Sebastien
    Pautas, Cecile
    Vekhoff, Anne
    Farhat, Hassan
    Suarez, Felipe
    Kuentz, Mathieu
    Cordonnier, Catherine
    BLOOD, 2007, 110 (11) : 153B - 153B
  • [28] SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF PALIVIZUMAB IN HIGH-RISK PATIENTS
    Paladio Duran, N.
    Garcia-Altes, A.
    Pons Rafols, J. M.
    Tebe Cordomi, C.
    VALUE IN HEALTH, 2009, 12 (07) : A432 - A432
  • [29] Cost-Effectiveness of Antifungal Strategies in High-Risk Neutropenic Patients
    Schwarzinger, Michael
    Baillot, Sylvain
    Beauchamp, Celine
    Maury, Sebastien
    Pautas, Cecile
    Vekhoff, Anne
    Farhat, Hassan
    Suarez, Felipe
    Hemery, Francois
    Kuentz, Mathieu
    Cordonnier, Catherine
    BLOOD, 2008, 112 (11) : 475 - 475
  • [30] Safety and cost-effectiveness of MIDCABG in high-risk CABG patients
    Del Rizzo, DF
    Boyd, WD
    Novick, RJ
    McKenzie, FN
    Desai, ND
    Menkis, AH
    ANNALS OF THORACIC SURGERY, 1998, 66 (03): : 1002 - 1007
12345